Cargando…

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis

BACKGROUND: Non-alcoholic fatty liver disease is a prohaemostatic state with abnormal primary, secondary and tertiary haemostasis. Plasminogen activator inhibitor (PAI)-1 is the best-established marker for prohaemostasis in non-alcoholic fatty liver disease. While epidemiological studies demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rivas, Gloriany, Hummer-Bair, Breianna, Bezinover, Dmitri, Kadry, Zakiyah, Stine, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330585/ https://www.ncbi.nlm.nih.gov/pubmed/34341018 http://dx.doi.org/10.1136/bmjgast-2021-000683

Ejemplares similares

Mobile health lifestyle intervention program leads to clinically significant loss of body weight in patients with NASH
por: Stine, Jonathan G., et al.
Publicado: (2023)

Negative impact of the pandemic on hospital admissions, morbidity and early mortality for acute cirrhosis decompensation
por: Gananandan, Kohilan, et al.
Publicado: (2023)

Inherited thrombophilia and portal vein thrombosis in cirrhosis: A systematic review and meta‐analysis
por: Ma, Steven D., et al.
Publicado: (2019)

Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH
por: Stine, Jonathan G., et al.
Publicado: (2020)

PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis
por: Dunn, Winston, et al.
Publicado: (2019)

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
por: Monteiro, Sofia, et al.
Publicado: (2021)

Predicting 1-year mortality among patients with decompensated cirrhosis: results of a multicentre evaluation of the Bristol Prognostic Score
por: Bowers, Sarah Pauline, et al.
Publicado: (2022)

Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis
por: Khamri, Wafa, et al.
Publicado: (2022)

Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)
por: Weiss, Emmanuel, et al.
Publicado: (2023)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
por: Xie, Yanan, et al.
Publicado: (2022)

Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case–control study
por: Xu, Xiaomei, et al.
Publicado: (2021)

SIRT1-dependent mechanisms and effects of resveratrol for amelioration of muscle wasting in NASH mice
por: Liu, Chih-Wei, et al.
Publicado: (2020)

Effect of COVID-19 on presentations of decompensated liver disease in Scotland
por: Manship, Thomas, et al.
Publicado: (2022)

Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH)
por: Chawla, Kashmira S, et al.
Publicado: (2016)

Emergent Management of Intracardiac Thrombosis during Liver Transplantation
por: Protin, Caroline, et al.
Publicado: (2016)

Hepatic decompensation in the absence of obvious precipitants: the potential role of cytomegalovirus infection/reactivation
por: Rosi, Silvia, et al.
Publicado: (2015)

The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa
por: Lemoine, Maud, et al.
Publicado: (2016)

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial
por: Vilar Gomez, Eduardo, et al.
Publicado: (2011)

A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study
por: Mao, Hao-dan, et al.
Publicado: (2023)

Autoimmune conditions are associated with perioperative thrombotic complications in liver transplant recipients: A UNOS database analysis
por: Bezinover, Dmitri, et al.
Publicado: (2016)

Changing trends of hospitalisation of liver cirrhosis in Beijing, China
por: Bao, Xiao-Yuan, et al.
Publicado: (2015)

High plasma soluble thrombomodulin levels indicated poor prognosis of decompensated liver cirrhosis: a prospective cohort study
por: Wei, Xinhuan, et al.
Publicado: (2022)

Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease
por: Konerman, Monica A, et al.
Publicado: (2019)

Aflatoxin B(1) exposure and liver cirrhosis in Guatemala: a case–control study
por: Alvarez, Christian S, et al.
Publicado: (2020)

Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis
por: Sripongpun, Pimsiri, et al.
Publicado: (2021)

Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
por: Johnson, Amy L, et al.
Publicado: (2021)

Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies
por: Middleton, Paul, et al.
Publicado: (2021)

A novel smartphone scleral‐image based tool for assessing jaundice in decompensated cirrhosis patients
por: Kazankov, Konstantin, et al.
Publicado: (2023)

Factors associated with renal dysfunction in hepatitis C-related cirrhosis and its correlation with Child-Pugh score
por: Bhatti, Hamza Waqar, et al.
Publicado: (2019)

Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis
por: Khan, Adnan Aman, et al.
Publicado: (2020)

Development of a national Department of Veterans Affairs mortality risk prediction model among patients with cirrhosis
por: Koola, Jejo David, et al.
Publicado: (2019)

Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort study
por: Lee, Nerissa Hoi Ching, et al.
Publicado: (2023)

Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function
por: Blasco-Algora, Sara, et al.
Publicado: (2016)

Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
por: Elsayed, Amr, et al.
Publicado: (2020)

Excellent outcomes with liver transplantation in hepatopulmonary syndrome across pre-transplant PaO(2) spectrum
por: Kadry, Zakiyah, et al.
Publicado: (2021)

Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study
por: Theel, Willy B, et al.
Publicado: (2023)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation
por: Yuan, Lunzhi, et al.
Publicado: (2019)

Lower survival and higher rates of cirrhosis in patients with ROUX-EN-Y gastric bypass hospitalised with alcohol-associated hepatitis
por: Anugwom, Chimaobi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k9jsgg6lee6vfbhsvflf8mt242